|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0026882,
umls-concept:C0030664,
umls-concept:C0030705,
umls-concept:C0034804,
umls-concept:C0034833,
umls-concept:C0079419,
umls-concept:C0242957,
umls-concept:C0346153,
umls-concept:C0376571,
umls-concept:C0598034,
umls-concept:C1441616,
umls-concept:C1514307,
umls-concept:C2745888
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2002-4-30
|
|
pubmed:abstractText |
The morphologic and molecular phenotype of breast cancers may help identify patients who are likely to carry germline mutations in BRCA1 and BRCA2. This study evaluates the immunohistochemical profiles of tumors arising in patients with mutations in these genes.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2310-8
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:11981002-Adult,
pubmed-meshheading:11981002-Breast Neoplasms,
pubmed-meshheading:11981002-Chi-Square Distribution,
pubmed-meshheading:11981002-Female,
pubmed-meshheading:11981002-Genes, BRCA1,
pubmed-meshheading:11981002-Genes, BRCA2,
pubmed-meshheading:11981002-Germ-Line Mutation,
pubmed-meshheading:11981002-Humans,
pubmed-meshheading:11981002-Immunoenzyme Techniques,
pubmed-meshheading:11981002-Immunophenotyping,
pubmed-meshheading:11981002-Logistic Models,
pubmed-meshheading:11981002-Predictive Value of Tests,
pubmed-meshheading:11981002-Receptor, erbB-2,
pubmed-meshheading:11981002-Receptors, Estrogen,
pubmed-meshheading:11981002-Receptors, Progesterone,
pubmed-meshheading:11981002-Tumor Suppressor Protein p53
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
|
|
pubmed:affiliation |
Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research and the Royal Marsden Hospital, London, United Kingdom. lakhani@icr.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
